title: [Clinical signs of endothelial disorders in patients with severe sepsis].
abstract: A clinical-experimental study was carried out. The objective was to find some regularities in endothelial disorder progression in patients with severe sepsis and to evaluate clinical efficacy of some methods of hepatic protection. Experimental part of work was carried out on 59 mice with induced peritonitis. Obtained data shows early emergence of lung disorders that precede changes in hepatic tissue. Clinical part of work included 181 patient with severe sepsis. It was noted that acute respiratory distress syndrome symptoms occurred earlier than hepatic dysfunction, if the latter joints, it aggravates the patients status and worsens the prognosis. Use of Heptral (Ademetionine) and Ketamine in order to protect liver is a clinically effective method which makes possible to decrease the lethality.
authors: L L
authors: LL
authors: Plotkin
authors: A M
authors: AM
authors: Bespalov
authors: D M
authors: DM
authors: Smirnov
authors: N N
authors: NN
authors: Timchenko
authors: Iu S
authors: IuS
authors: Shapovalova
authors: A B
authors: AB
authors: Konradi
mesh_terms: D018806:APACHE; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D015415:Biomarkers / Q000032:analysis; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology*; D005260:Female; D048550:Hepatic Insufficiency / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D007511:Ischemia / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D007649:Ketamine / Q000008:administration & dosage / Q000627:therapeutic use; D008099:Liver / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D008168:Lung / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D008297:Male; D051379:Mice; D008875:Middle Aged; D051381:Rats; D012128:Respiratory Distress Syndrome / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D012436:S-Adenosylmethionine / Q000008:administration & dosage / Q000627:therapeutic use; D018805:Sepsis / Q000150:complications / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D055815:Young Adult
chemical_list: D015415:Biomarkers; D007649:Ketamine; D012436:S-Adenosylmethionine